$1.120
-0.039 (-3.45%)At close
COCP News
COCP Events
Cocrystal Pharma Secures $5M Investment from Opko Health
Cocrystal Pharma (COCP) announced a $5M investment from Opko Health (OPK) as the company advances its lead norovirus program toward Phase 1b topline data later this year. Under the terms of the agreement, Cocrystal sold 5,474,053 shares of its common stock to Opko at a price per share of $0.9134, the Nasdaq consolidated bid price on the trading day of closing, for proceeds to the company of $5M. No warrants or other derivative securities were included in the transaction.
Cocrystal Pharma Secures $5M Investment from OPKO Health
Cocrystal Pharma (COCP) announced a $5M investment from OPKO Health (OPK), a longtime investor in the company. Under the terms of the agreement, Cocrystal sold 5,474,053 shares of its common stock to OPKO at a price per share of $0.9134, the Nasdaq Consolidated Bid Price on the trading day of closing, for proceeds to the company of $5M. No warrants or other derivative securities were included in the transaction.
Cocrystal Pharma Appoints James Sapirstein as CEO
Cocrystal Pharma has appointed James Sapirstein CEO, effective immediately. The company also plans to appoint Sapirstein as a member of the board of directors. Sapirstein replaces Sam Lee and Jim Martin, who served as co-CEOs. Sam Lee will continue as president and transition to chief scientific officer, and Jim Martin will continue as CFO. Sapirstein was CEO of Contravir Pharmaceuticals.
Cocrystal Pharma Files $150M Mixed Securities Shelf
Cocrystal Pharma files $150M mixed securities shelf
Cocrystal Pharma Receives FDA Fast Track Designation
Cocrystal Pharma announced that the FDA has granted Fast Track designation to its oral, direct-acting protease inhibitor, CDI-988, the first oral antiviral candidate being developed for treatment and prophylaxis of norovirus infection.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.